First-Line Immunotherapy Combo Boosts Survival in Unresectable Liver Cancer

(MedPage Today) -- First-line treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) significantly improved survival compared with lenvatinib (Lenvima) or sorafenib (Nexavar) for patients with unresectable hepatocellular carcinoma (HCC), the...